Eu­ro­pean reg­u­la­tors are lock­ing the door on Sarep­ta’s Duchenne drug — but they aren’t throw­ing away the key

Sarep­ta Ther­a­peu­tics $SRPT won’t be sell­ing its Duchenne mus­cu­lar dy­s­tro­phy drug eteplirsen in Eu­rope any­time soon.

Eu­ro­pean reg­u­la­tors at the CHMP con­firmed their thumbs-down on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER